LYRA News and Press, Lyra Therapeutics Inc. From 03/09/22

Lyra Therapeutics press release (NASDAQ:LYRA): FY GAAP EPS of -$3.35 misses by $0.23. Cash and cash equivalents as of December 31, 2021 were $45.7 million, compared with $58.1 million as of September 30, 2021. Shares -1.18% PM. For further details see: Lyra Therapeutics GAAP EPS of -$3....

Lyra Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update Treated first patient in pivotal Phase 3 ENLIGHTEN program for surgically naïve chronic rhinosinusitis patients Initiated BEACON Phase 2 trial for LYR-220 in chro...

Lyra Therapeutics Appoints Jim Tobin to Board of Directors Biopharmaceutical leader brings decades of expertise with C-suite tenures at Boston Scientific, Biogen and Baxter International PR Newswire WATERTOWN, Mass. , March 7, 2022 /PRNewswire/ -- Lyra Therap...

Lyra Therapeutics (NASDAQ:LYRA) enrolled the first patient in a phase 3 ENLIGHTEN I trial of LYR-210 in adult patients with chronic rhinosinusitis (CRS). The company said LYR-210 is designed as an alternative to sinus surgery. The ENLIGHTEN program will consist of two, staggered phase 3 studi...

Lyra Therapeutics Announces First Patient Dosed in Pivotal ENLIGHTEN I Clinical Trial of LYR-210 in Chronic Rhinosinusitis Patients PR Newswire WATERTOWN, Mass. , Feb. 28, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics ...

The following slide deck was published by Lyra Therapeutics, Inc. in conjunction with this event. For further details see: Lyra Therapeutics (LYRA) Investor Presentation - Slideshow

Lyra Therapeutics Appoints Harlan W. Waksal, MD, as Executive Chairman Recent President and Chief Executive Officer of Kadmon brings vast experience leading and scaling late-stage and commercial biopharmaceutical companies PR Newswire WATERTOWN, Mass. , Feb. 17...

Lyra Therapeutics Announces Initiation of LYR-210 Pivotal Phase 3 ENLIGHTEN Program in Surgically Naïve Chronic Rhinosinusitis Patients Company also announces initiation of BEACON clinical study of LYR-220 in previously operated chronic rhinosinusitis patients LYR-210 a...

Lyra Therapeutics to Present at Upcoming Virtual Investor Conferences PR Newswire WATERTOWN, Mass. , Nov. 11, 2021 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform...

Lyra Therapeutics, Inc. (LYRA) Q3 2021 Earnings Conference Call November 09, 2021, 04:30 PM ET Company Participants Stephanie Marks - Argot Partners Maria Palasis - President and CEO Jason Cavalier - CFO Robert Kern - Chief Medical Officer Corinne Noyes - SVP-Commercial Strategy & Market ...